{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:32:11Z","timestamp":1792467131508,"version":"4.5.0"},"reference-count":132,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Heart failure (HF) represents a significant global health challenge, characterized by high morbidity and mortality rates, and imposes considerable burdens on healthcare systems and patient quality of life. Traditional management strategies, primarily relying on clinical assessments and standard biomarkers like natriuretic peptides, face limitations due to the heterogeneity of HF. This review aims to delve into the evolving landscape of non-natriuretic biomarkers and the transformative potential of omics technologies, underscoring their roles in advancing HF treatment towards precision medicine. By offering novel insights into the biological underpinnings of HF, including inflammation, myocardial stress, fibrosis, and metabolic disturbances, these advancements facilitate more accurate patient phenotyping and individualized treatment strategies. The integration of non-natriuretic biomarkers and omics technologies heralds a pivotal shift in HF management, enabling a move towards tailored therapeutic interventions. This approach promises to enhance clinical outcomes by improving diagnostic accuracy, risk stratification, and monitoring therapeutic responses. However, challenges such as the variability in biomarker levels, cost-effectiveness, and the standardization of biomarker testing across different healthcare settings pose hurdles to their widespread adoption. Despite these challenges, the promise of precision medicine in HF, driven by these innovative biomarkers and technologies, offers a new horizon for improving patient care and outcomes. This review advocates for the further integration of these advancements into clinical practice, highlighting the need for ongoing research to fully realize their potential in transforming the landscape of heart failure management.<\/jats:p>","DOI":"10.3390\/biom14030309","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T04:03:50Z","timestamp":1709697830000},"page":"309","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-9240","authenticated-orcid":false,"given":"Roberto","family":"Licordari","sequence":"first","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-253X","authenticated-orcid":false,"given":"Michele","family":"Correale","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, Policlinico Riuniti University Hospital, 71100 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7161-3224","authenticated-orcid":false,"given":"Matteo","family":"Beltrami","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50124 Florence, Italy"},{"name":"Arrhythmia and Electrophysiology Unit, Careggi University Hospital, 50124 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2379-1960","authenticated-orcid":false,"given":"Michele","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Micari","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-984X","authenticated-orcid":false,"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, Le Scotte Hospital, University of Siena, 84081 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dattilo","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","article-title":"Established and Emerging Roles of Biomarkers in Heart Failure","volume":"123","author":"Ibrahim","year":"2018","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dattilo, G., Laterra, G., Licordari, R., Parisi, F., Pistelli, L., Colarusso, L., Zappia, L., Vaccaro, V., Demurtas, E., and Allegra, M. (2023). The Long-Term Benefit of Sacubitril\/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196247"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/phar.2626","article-title":"NR3C2 Genotype Is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldo-DHF Trial","volume":"41","author":"Dumeny","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ejhf.1716","article-title":"Effects of Spironolactone on Serum Markers of Fibrosis in People at High Risk of Developing Heart Failure: Rationale, Design and Baseline Characteristics of a Proof-of-concept, Randomised, Precision-medicine, Prevention Trial. The Heart OMics in AGing (HOMAGE) Trial","volume":"22","author":"Pellicori","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2020.03.007","article-title":"Precision Medicine in Distinct Heart Failure Phenotypes: Focus on Clinical Epigenetics","volume":"224","author":"Napoli","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium\u2013Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Fragasso","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Biasucci, L.M., Maino, A., Grimaldi, M.C., Cappannoli, L., and Aspromonte, N. (2021). Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132771"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cardfail.2023.03.001","article-title":"Leveraging Biomarkers for Precision Medicine in Heart Failure","volume":"29","author":"Kennedy","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1253\/circj.CJ-20-1299","article-title":"Risk Stratification Towards Precision Medicine in Heart Failure\u2014Current Progress and Future Perspectives","volume":"85","author":"Nagai","year":"2021","journal-title":"Circ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.36628\/ijhf.2020.0036","article-title":"Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment","volume":"3","author":"Wettersten","year":"2021","journal-title":"Int. J. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10741-019-09807-z","article-title":"Biomarkers in Heart Failure: The Past, Current and Future","volume":"24","author":"Sarhene","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3343\/alm.2023.43.3.225","article-title":"Biomarkers in Heart Failure: From Research to Clinical Practice","volume":"43","author":"Berezin","year":"2023","journal-title":"Ann. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/eurjhf\/hfr059","article-title":"Directions from Hecate: Towards a Multi-Marker Approach for Heart Failure Assessment","volume":"13","author":"Kakkar","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_15","first-page":"e137","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"145","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","first-page":"e42081","article-title":"Novel Biomarkers and the Multiple-Marker Approach in Early Detection, Prognosis, and Risk Stratification of Cardiac Diseases: A Narrative Review","volume":"15","author":"Ullah","year":"2023","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_19","first-page":"VI40","article-title":"Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure. Relations to Survival and the Effects of Therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Francis","year":"1993","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/euhj.2001.2977","article-title":"Chromogranin A in Heart Failure. A Novel Neurohumoral Factor and a Predictor for Mortality","volume":"23","author":"Ceconi","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/CIRCHEARTFAILURE.109.867747","article-title":"Chromogranin B in Heart Failure: A Putative Cardiac Biomarker Expressed in the Failing Myocardium","volume":"3","author":"Husberg","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjcard.2011.03.034","article-title":"Prognostic Value of Plasma Renin Activity in Heart Failure","volume":"108","author":"Vergaro","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ejhf.973","article-title":"Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ejhf.1366","article-title":"Adrenomedullin in Heart Failure: Pathophysiology and Therapeutic Application","volume":"21","author":"Voors","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","article-title":"Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea","volume":"55","author":"Maisel","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/eurheartj\/ehs136","article-title":"Mid-Regional pro-Atrial Natriuretic Peptide and pro-Adrenomedullin Testing for the Diagnostic and Prognostic Evaluation of Patients with Acute Dyspnoea","volume":"33","author":"Shah","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2005.03.003","article-title":"Neurohormonal Activation in Congestive Heart Failure and the Role of Vasopressin","volume":"95","author":"Chatterjee","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/CIRCHEARTFAILURE.110.960096","article-title":"Increased 90-Day Mortality in Patients with Acute Heart Failure with Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study","volume":"4","author":"Maisel","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cca.2017.10.001","article-title":"Copeptin in Heart Failure: Review and Meta-Analysis","volume":"475","author":"Zhong","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e9342","DOI":"10.1097\/MD.0000000000009342","article-title":"Plasma Endothelin-1-Related Peptides as the Prognostic Biomarkers for Heart Failure: A PRISMA-Compliant Meta-Analysis","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.456","article-title":"Increased Mortality with Elevated Plasma Endothelin-1 in Acute Heart Failure: An ASCEND-HF Biomarker Substudy","volume":"18","author":"Perez","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcp\/aqx014","article-title":"Systematic Evaluation of Endothelin 1 Measurement Relative to Traditional and Modern Biomarkers for Clinical Assessment and Prognosis in Patients with Chronic Systolic Heart Failure","volume":"147","author":"Gaggin","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cca.2017.09.003","article-title":"Urocortins: Actions in Health and Heart Failure","volume":"474","author":"Rademaker","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","article-title":"Emerging Biomarkers in Heart Failure","volume":"58","author":"Januzzi","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_35","first-page":"89","article-title":"Circulating Biomarkers in Heart Failure","volume":"Volume 1067","author":"Islam","year":"2018","journal-title":"Heart Failure: From Research to Clinical Practice"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.106.655076","article-title":"Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients with Stable Chronic Heart Failure","volume":"116","author":"Latini","year":"2007","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis","volume":"137","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.15420\/cfr.2015.1.2.102","article-title":"Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA Role of Cardiac Troponin Levels in Acute Heart Failure","volume":"1","author":"Wettersten","year":"2015","journal-title":"Card. Fail. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/eurjhf\/hfq210","article-title":"Serial Changes in High-sensitive Troponin I Predict Outcome in Patients with Decompensated Heart Failure","volume":"13","author":"Xue","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ahj.2012.03.015","article-title":"Highly Sensitive Troponin T for Risk Stratification of Acutely Destabilized Heart Failure","volume":"163","author":"Casas","year":"2012","journal-title":"Am. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ejhf.2256","article-title":"Concentration-dependent Clinical and Prognostic Importance of High-sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: The EMPEROR-Reduced Trial","volume":"23","author":"Packer","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03194597","article-title":"The Multigene Family of Fatty Acid-Binding Proteins (FABPs): Function, Structure and Polymorphism","volume":"47","year":"2006","journal-title":"J. Appl. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.106.641936","article-title":"Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients with Acute Coronary Syndromes","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0002-9343(02)01394-3","article-title":"Use of Cytosolic and Myofibril Markers in the Detection of Ongoing Myocardial Damage in Patients with Chronic Heart Failure","volume":"113","author":"Setsuta","year":"2002","journal-title":"Am. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinbiochem.2017.02.014","article-title":"Circulating Intestinal Fatty Acid-Binding Protein (I-FABP) Levels in Acute Decompensated Heart Failure","volume":"50","author":"Kitai","year":"2017","journal-title":"Clin. Biochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.amjms.2016.08.018","article-title":"Heart-Type Fatty Acid Binding Protein in the Assessment of Acute Pulmonary Embolism","volume":"352","author":"Qian","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6984845","DOI":"10.1155\/2019\/6984845","article-title":"Glutathione Transferase P1 Polymorphism Might Be a Risk Determinant in Heart Failure","volume":"2019","author":"Simeunovic","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cardfail.2011.11.003","article-title":"Serum Glutathione S-Transferase P1 1 in Prediction of Cardiac Function","volume":"18","author":"Andrukhova","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_52","first-page":"690205","article-title":"Prognostic Value of Galectin-3 in Patients with Heart Failure","volume":"2015","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2353\/ajpath.2007.060906","article-title":"Interferon-\u03b3 Induces Chronic Active Myocarditis and Cardiomyopathy in Transgenic Mice","volume":"171","author":"Reifenberg","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","article-title":"Elevated Plasma Galectin-3 Is Associated with near-Term Rehospitalization in Heart Failure: A Pooled Analysis of 3 Clinical Trials","volume":"167","author":"Meijers","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1354750X.2017.1319421","article-title":"The GALA Study: Relationship between Galectin-3 Serum Levels and Short- and Long-Term Outcomes of Patients with Acute Heart Failure","volume":"22","author":"Mueller","year":"2017","journal-title":"Biomarkers"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","article-title":"Galectin-3 in Heart Failure","volume":"14","author":"Gehlken","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and Prognostic Significance of sST2 in Heart Failure","volume":"74","author":"Aimo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jchf.2016.12.016","article-title":"Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure","volume":"5","author":"Aimo","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cardfail.2008.06.415","article-title":"Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure","volume":"14","author":"Boisot","year":"2008","journal-title":"J. Card. Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jacc.2017.09.026","article-title":"Prognostic Value of Serial ST2 Measurements in Patients with Acute Heart Failure","volume":"70","author":"Baart","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 Predicts Outcome in Chronic Heart Failure Beyond NT\u2212proBNP and High-Sensitivity Troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/00015385.2017.1325617","article-title":"Prognostic Value of sST2 and NT-proBNP at Admission in Heart Failure with Preserved, Mid-Ranged and Reduced Ejection Fraction","volume":"73","author":"Huang","year":"2018","journal-title":"Acta Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.dsx.2015.09.016","article-title":"Diabetes Mellitus Related Biomarker: The Predictive Role of Growth-Differentiation Factor-15","volume":"10","author":"Berezin","year":"2016","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rochette, L., Dogon, G., Zeller, M., Cottin, Y., and Vergely, C. (2021). GDF15 and Cardiac Cells: Current Concepts and New Insights. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168889"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ejhf.331","article-title":"Growth Differentiation Factor 15 (GDF-15) in Patients Admitted for Acute Heart Failure: Results from the RELAX-AHF Study","volume":"17","author":"Cotter","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","article-title":"Prognostic Utility of Growth Differentiation Factor-15 in Patients with Chronic Heart Failure","volume":"50","author":"Kempf","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.109.928846","article-title":"Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial","volume":"122","author":"Anand","year":"2010","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1157043","DOI":"10.3389\/fphar.2023.1157043","article-title":"The Role of \u03b2-Catenin in Cardiac Diseases","volume":"14","author":"Ni","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Procopio, M.C., Lauro, R., Nasso, C., Carerj, S., Squadrito, F., Bitto, A., Di Bella, G., Micari, A., Irrera, N., and Costa, F. (2021). Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020204"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lofrumento, F., Irrera, N., Licordari, R., Perfetti, S., Nasso, E., Liotta, P., Isgr\u00f2, G., Garcia-Ruiz, V., Squadrito, F., and Carerj, S. (2023). Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation. IJMS, 24.","DOI":"10.3390\/ijms242417546"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12964-020-00555-4","article-title":"TGF-\u03b2 and WNT Signaling Pathways in Cardiac Fibrosis: Non-Coding RNAs Come into Focus","volume":"18","author":"Yousefi","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCRESAHA.113.300226","article-title":"Non-Coding RNAs in Cardiac Remodeling and Heart Failure","volume":"113","author":"Kumarswamy","year":"2013","journal-title":"Circ. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1172\/JCI36154","article-title":"MicroRNA-208a Is a Regulator of Cardiac Hypertrophy and Conduction in Mice","volume":"119","author":"Callis","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm.2282","article-title":"miR-499 Regulates Mitochondrial Dynamics by Targeting Calcineurin and Dynamin-Related Protein-1","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCRESAHA.117.312117","article-title":"LncRNA ZFAS1 as a SERCA2a Inhibitor to Cause Intracellular Ca2+ Overload and Contractile Dysfunction in a Mouse Model of Myocardial Infarction","volume":"122","author":"Zhang","year":"2018","journal-title":"Circ. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.7150\/thno.50990","article-title":"Ablation of lncRNA Miat Attenuates Pathological Hypertrophy and Heart Failure","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"950284","DOI":"10.3389\/fcvm.2022.950284","article-title":"Long Non-Coding RNAs in the Pathogenesis of Heart Failure: A Literature Review","volume":"9","author":"Fan","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10557-017-6752-z","article-title":"Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets","volume":"31","author":"Ayoub","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0002-8703(56)90099-0","article-title":"A Study of C-Reactive Protein in the Serum of Patients with Congestive Heart Failure","volume":"51","author":"Elster","year":"1956","journal-title":"Am. Heart J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative Stress and Inflammation in the Evolution of Heart Failure: From Pathophysiology to Therapeutic Strategies","volume":"27","author":"Aimo","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Inflammatory Markers and Risk of Heart Failure in Elderly Subjects without Prior Myocardial Infarction: The Framingham Heart Study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/01.CIR.0000097109.90783.FC","article-title":"Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study","volume":"108","author":"Cesari","year":"2003","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jchf.2019.12.005","article-title":"Clinical Role of CA125 in Worsening Heart Failure","volume":"8","author":"Barallat","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-019-03656-y","article-title":"Role of Oxidative Stress-Related Biomarkers in Heart Failure: Galectin 3, A1-Antitrypsin and LOX-1: New Therapeutic Perspective?","volume":"464","author":"Lubrano","year":"2020","journal-title":"Mol. Cell Biochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0735-1097(00)00717-8","article-title":"Effects of Insulin-Glucose Infusion on Left Ventricular Function at Rest and during Dynamic Exercise in Healthy Subjects and Noninsulin Dependent Diabetic Patients","volume":"36","author":"Sasso","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Marfella, R., and Sardu, C. (2021). Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules, 11.","DOI":"10.3390\/biom11121834"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10741-019-09806-0","article-title":"Pathogenesis and Pathophysiology of Heart Failure with Reduced Ejection Fraction: Translation to Human Studies","volume":"24","author":"Ge","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/CIRCHEARTFAILURE.111.965020","article-title":"Multiple Biomarkers for Risk Prediction in Chronic Heart Failure","volume":"5","author":"Ky","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ejhf.749","article-title":"A Multimarker Multi-Time Point-Based Risk Stratification Strategy in Acute Heart Failure: Results from the RELAX-AHF Trial","volume":"19","author":"Demissei","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_92","first-page":"824","article-title":"Evaluation of Eight Biomarkers to Predict Short-Term Mortality in Patients with Acute Severe Dyspnea","volume":"83","author":"Bonadona","year":"2017","journal-title":"Minerva Anestesiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jacc.2019.12.069","article-title":"Multiple Plasma Biomarkers for Risk Stratification in Patients with Heart Failure and Preserved Ejection Fraction","volume":"75","author":"Chirinos","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"76B","DOI":"10.1016\/j.amjcard.2015.01.045","article-title":"Multimarker Testing with ST2 in Chronic Heart Failure","volume":"115","author":"Richards","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1373\/clinchem.2019.308478","article-title":"Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure","volume":"65","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.117.311002","article-title":"Cardiovascular Metabolomics","volume":"122","author":"McGarrah","year":"2018","journal-title":"Circ. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cjca.2018.12.039","article-title":"Ensembling Electrical and Proteogenomics Biomarkers for Improved Prediction of Cardiac-Related 3-Month Hospitalizations: A Pilot Study","volume":"35","author":"Singh","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sethi, Y., Patel, N., Kaka, N., Kaiwan, O., Kar, J., Moinuddin, A., Goel, A., Chopra, H., and Cavalu, S. (2023). Precision Medicine and the Future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review. JCM, 12.","DOI":"10.3390\/jcm12051799"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Evans, G.A. (2000). Designer Science and the \u201cOmic\u201d Revolution. Nat. Biotechnol., 18.","DOI":"10.1038\/72480"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1373\/clinchem.2016.263350","article-title":"Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics","volume":"63","author":"Apple","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1074\/mcp.R800007-MCP200","article-title":"The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery","volume":"7","author":"Edwards","year":"2008","journal-title":"Mol. Cell Proteom."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2018.08.2181","article-title":"Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations","volume":"72","author":"Cuenca","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41467-019-13690-5","article-title":"Genome-Wide Association and Mendelian Randomisation Analysis Provide Insights into the Pathogenesis of Heart Failure","volume":"11","author":"Shah","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"688","DOI":"10.15252\/emmm.201506174","article-title":"The Impact of Genome-Wide Association Studies on the Pathophysiology and Therapy of Cardiovascular Disease","volume":"8","author":"Kessler","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/CIRCRESAHA.115.306566","article-title":"Genetics of Coronary Artery Disease","volume":"118","author":"McPherson","year":"2016","journal-title":"Circ. Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yang, J., Xu, W.-W., and Hu, S.-J. (2015). Heart Failure: Advanced Development in Genetics and Epigenetics. Biomed. Res. Int., 2015.","DOI":"10.1155\/2015\/352734"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4330\/wjc.v8.i2.211","article-title":"Novel Epigenetic-Based Therapies Useful in Cardiovascular Medicine","volume":"8","author":"Napoli","year":"2016","journal-title":"World J. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1161\/CIRCULATIONAHA.111.040071","article-title":"Distinct Epigenomic Features in End-Stage Failing Human Hearts","volume":"124","author":"Movassagh","year":"2011","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/emmm.201201553","article-title":"Alterations in Cardiac DNA Methylation in Human Dilated Cardiomyopathy","volume":"5","author":"Haas","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/CIRCULATIONAHA.117.027355","article-title":"Epigenome-Wide Association Study Identifies Cardiac Gene Patterning and a Novel Class of Biomarkers for Heart Failure","volume":"136","author":"Meder","year":"2017","journal-title":"Circulation"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/1389202911314090006","article-title":"Will Global Transcriptome Analysis Allow the Detection of Novel Prognostic Markers in Coronary Artery Disease and Heart Failure?","volume":"14","author":"Gora","year":"2013","journal-title":"Curr. Genom."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ejhg.2012.129","article-title":"RNA-Seq and Human Complex Diseases: Recent Accomplishments and Future Perspectives","volume":"21","author":"Costa","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"353a","DOI":"10.1093\/eurheartj\/ehu180","article-title":"Genome-Wide Profiling of the Cardiac Transcriptome after Myocardial Infarction Identifies Novel Heart-Specific Long Non-Coding RNAs","volume":"36","author":"Ounzain","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5603\/CJ.a2017.0052","article-title":"Heart Failure: Pilot Transcriptomic Analysis of Cardiac Tissue by RNA-Sequencing","volume":"24","author":"Schiano","year":"2017","journal-title":"Cardiol. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ehf2.12136","article-title":"Differentiating Heart Failure Phenotypes Using Sex-Specific Transcriptomic and Proteomic Biomarker Panels","volume":"4","author":"Toma","year":"2017","journal-title":"ESC Heart Fail."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/eurheartj\/ehs162","article-title":"Unbiased Plasma Proteomics for Novel Diagnostic Biomarkers in Cardiovascular Disease: Identification of Quiescin Q6 as a Candidate Biomarker of Acutely Decompensated Heart Failure","volume":"33","author":"Mebazaa","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-016-0774-3","article-title":"Combining Patient Proteomics and in Vitro Cardiomyocyte Phenotype Testing to Identify Potential Mediators of Heart Failure with Preserved Ejection Fraction","volume":"14","author":"Raphael","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.carpath.2016.10.001","article-title":"Altered Protein Levels in the Isolated Extracellular Matrix of Failing Human Hearts with Dilated Cardiomyopathy","volume":"26","author":"DeAguero","year":"2017","journal-title":"Cardiovasc. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ejhf.980","article-title":"Circulating Proteins as Predictors of Incident Heart Failure in the Elderly","volume":"20","author":"Stenemo","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2006.06.063","article-title":"Cardiovascular Proteomics: Tools to Develop Novel Biomarkers and Potential Applications","volume":"48","author":"Arab","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/eurjhf\/hfr151","article-title":"Association of Galectin-3 and Fibrosis Markers with Long-term Cardiovascular Outcomes in Patients with Heart Failure, Left Ventricular Dysfunction, and Dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial","volume":"14","author":"Rossignol","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amjmed.2019.07.041","article-title":"CA125-Guided Diuretic Treatment Versus Usual Care in Patients with Acute Heart Failure and Renal Dysfunction","volume":"133","author":"Bonanad","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/CIRCHEARTFAILURE.113.000457","article-title":"Soluble Concentrations of the Interleukin Receptor Family Member ST2 and \u03b2-Blocker Therapy in Chronic Heart Failure","volume":"6","author":"Gaggin","year":"2013","journal-title":"Circ Heart Fail."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e000032","DOI":"10.1161\/HCG.0000000000000032","article-title":"Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association","volume":"10","author":"Cheng","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e003190","DOI":"10.1161\/JAHA.115.003190","article-title":"Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure with Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure","volume":"5","author":"Hunter","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2015.10.079","article-title":"Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility with Mechanical Circulatory Support","volume":"67","author":"Ahmad","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hfc.2017.08.011","article-title":"Metabolic Biomarkers in Heart Failure","volume":"14","author":"Albert","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Du, Z., Shen, A., Huang, Y., Su, L., Lai, W., Wang, P., Xie, Z., Xie, Z., Zeng, Q., and Ren, H. (2014). 1H-NMR-Based Metabolic Analysis of Human Serum Reveals Novel Markers of Myocardial Energy Expenditure in Heart Failure Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088102"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Wang, J., Li, Z., Chen, J., Zhao, H., Luo, L., Chen, C., Xu, X., Zhang, W., Gao, K., and Li, B. (2013). Metabolomic Identification of Diagnostic Plasma Biomarkers in Humans with Chronic Heart Failure. Mol. BioSyst., 9.","DOI":"10.1039\/c3mb70227h"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Desmoulin, F., Galinier, M., Trouillet, C., Berry, M., Delmas, C., Turkieh, A., Massabuau, P., Taegtmeyer, H., Smih, F., and Rouet, P. (2013). Metabonomics Analysis of Plasma Reveals the Lactate to Cholesterol Ratio as an Independent Prognostic Factor of Short-Term Mortality in Acute Heart Failure. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060737"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10989-011-9254-z","article-title":"Isolation and Characterization of a Natriuretic Peptide from Crotalus Oreganus Abyssus (Grand Canyon Rattlesnake) and Its Effects on Systemic Blood Pressure and Nitrite Levels","volume":"17","author":"Almeida","year":"2011","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kolur, V., Vastrad, B., Vastrad, C., Kotturshetti, S., and Tengli, A. (2021). Identification of Candidate Biomarkers and Therapeutic Agents for Heart Failure by Bioinformatics Analysis. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02146-8"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/3\/309\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:45Z","timestamp":1760105385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/3\/309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":132,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["biom14030309"],"URL":"https:\/\/doi.org\/10.3390\/biom14030309","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}